Clinical trial
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or…
NCT00422877 · American Regent, Inc., Industry · Terminated
Key facts
| NCT number | NCT00422877 |
|---|---|
| Title | Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract |
| Official title | Phase II Open-Label Study of Weekly Taxoprexin® (DHA-paclitaxel) Injection as Second Line Therapy for Patients With Advanced Primary Cancers of the Liver, Including Hepatocellular Carcinoma and Carcinoma of the Gallbladder or Biliary Tract |
| Lead sponsor | American Regent, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer of the Liver |
| Intervention type | Drug |
| Interventions | Taxoprexin |
| Enrollment | 13 |
| Start date | Jan 1, 2007 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Jan 17, 2007 |
| Last update posted | Oct 16, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: